Circulating and tissue forms of the intestinal growth factor, glucagon- like peptide-2

Patricia L. Brubaker, Anna Crivici, Angelo Izzo, Peter Ehrlich, Anne Tsai, Daniel J. Drucker

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

Glucagon-like peptide-2 (GLP-2) has recently been identified as a stimulator of intestinal epithelial growth, prompting the development of RIA and HPLC methodologies to study this peptide in more detail. A GLP-2-specific antiserum (UTTH-7) was developed that recognizes amino acids 25-30 of human and rat GLP-2-(1-33). UTTH-7 cross-reacts with N- and C-terminally modified forms of GLP-2, proglucagon, and the major proglucagon fragment. Analysis of rat ileal extracts demonstrated the presence of GLP-2-(1-33) as well as significant amounts of GLP-2-(3-33) (16 ± 7% of total GLP-2). The level of total immunoreactive GLP-2 in plasma from fasted rats was 700 ± 71 pg/ml, and this increased 3.6-fold (P <0.001) in 24-h fed rate. HPLC analysis demonstrated the presence of both GLP-2-(1-33) and GLP-2-(3-38) in plasma from fasted rats, with increments in both peptides in plasma from fed rats. Immunoreactive GLP-2 increased in plasma from human subjects 2 h after a meal, rising from 851 ± 230 to 1106 ± 211 pg/ml (P <0.05); 15 ± 4% of this immunoreactivity was accounted for by the presence of intact GLP-2. HPLC showed the presence of both GLP-2-(1-33) and GLP-2-(3-33) in plasma from fed humans. Incubation of human GLP-2-(1-33) with the enzyme dipeptidylpeptidase IV resulted in liberation of GLP-2-(3-33), whereas replacement of Ala 2 with Gly 2 prevented this cleavage. Thus, while GLP-2-(1-33) is a major circulating and tissue form of GLP-2. GLP-2-(3-33) is a significant component of immunoreactive GLP-2 in both intestine and plasma.

Original languageEnglish (US)
Pages (from-to)4837-4843
Number of pages7
JournalEndocrinology
Volume138
Issue number11
DOIs
StatePublished - 1997
Externally publishedYes

Fingerprint

Glucagon-Like Peptide 2
Intercellular Signaling Peptides and Proteins
Proglucagon
High Pressure Liquid Chromatography

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Brubaker, P. L., Crivici, A., Izzo, A., Ehrlich, P., Tsai, A., & Drucker, D. J. (1997). Circulating and tissue forms of the intestinal growth factor, glucagon- like peptide-2. Endocrinology, 138(11), 4837-4843. https://doi.org/10.1210/en.138.11.4837

Circulating and tissue forms of the intestinal growth factor, glucagon- like peptide-2. / Brubaker, Patricia L.; Crivici, Anna; Izzo, Angelo; Ehrlich, Peter; Tsai, Anne; Drucker, Daniel J.

In: Endocrinology, Vol. 138, No. 11, 1997, p. 4837-4843.

Research output: Contribution to journalArticle

Brubaker, PL, Crivici, A, Izzo, A, Ehrlich, P, Tsai, A & Drucker, DJ 1997, 'Circulating and tissue forms of the intestinal growth factor, glucagon- like peptide-2', Endocrinology, vol. 138, no. 11, pp. 4837-4843. https://doi.org/10.1210/en.138.11.4837
Brubaker, Patricia L. ; Crivici, Anna ; Izzo, Angelo ; Ehrlich, Peter ; Tsai, Anne ; Drucker, Daniel J. / Circulating and tissue forms of the intestinal growth factor, glucagon- like peptide-2. In: Endocrinology. 1997 ; Vol. 138, No. 11. pp. 4837-4843.
@article{a302e8d0605a46b8ab7f6025b2b32afd,
title = "Circulating and tissue forms of the intestinal growth factor, glucagon- like peptide-2",
abstract = "Glucagon-like peptide-2 (GLP-2) has recently been identified as a stimulator of intestinal epithelial growth, prompting the development of RIA and HPLC methodologies to study this peptide in more detail. A GLP-2-specific antiserum (UTTH-7) was developed that recognizes amino acids 25-30 of human and rat GLP-2-(1-33). UTTH-7 cross-reacts with N- and C-terminally modified forms of GLP-2, proglucagon, and the major proglucagon fragment. Analysis of rat ileal extracts demonstrated the presence of GLP-2-(1-33) as well as significant amounts of GLP-2-(3-33) (16 ± 7{\%} of total GLP-2). The level of total immunoreactive GLP-2 in plasma from fasted rats was 700 ± 71 pg/ml, and this increased 3.6-fold (P <0.001) in 24-h fed rate. HPLC analysis demonstrated the presence of both GLP-2-(1-33) and GLP-2-(3-38) in plasma from fasted rats, with increments in both peptides in plasma from fed rats. Immunoreactive GLP-2 increased in plasma from human subjects 2 h after a meal, rising from 851 ± 230 to 1106 ± 211 pg/ml (P <0.05); 15 ± 4{\%} of this immunoreactivity was accounted for by the presence of intact GLP-2. HPLC showed the presence of both GLP-2-(1-33) and GLP-2-(3-33) in plasma from fed humans. Incubation of human GLP-2-(1-33) with the enzyme dipeptidylpeptidase IV resulted in liberation of GLP-2-(3-33), whereas replacement of Ala 2 with Gly 2 prevented this cleavage. Thus, while GLP-2-(1-33) is a major circulating and tissue form of GLP-2. GLP-2-(3-33) is a significant component of immunoreactive GLP-2 in both intestine and plasma.",
author = "Brubaker, {Patricia L.} and Anna Crivici and Angelo Izzo and Peter Ehrlich and Anne Tsai and Drucker, {Daniel J.}",
year = "1997",
doi = "10.1210/en.138.11.4837",
language = "English (US)",
volume = "138",
pages = "4837--4843",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "11",

}

TY - JOUR

T1 - Circulating and tissue forms of the intestinal growth factor, glucagon- like peptide-2

AU - Brubaker, Patricia L.

AU - Crivici, Anna

AU - Izzo, Angelo

AU - Ehrlich, Peter

AU - Tsai, Anne

AU - Drucker, Daniel J.

PY - 1997

Y1 - 1997

N2 - Glucagon-like peptide-2 (GLP-2) has recently been identified as a stimulator of intestinal epithelial growth, prompting the development of RIA and HPLC methodologies to study this peptide in more detail. A GLP-2-specific antiserum (UTTH-7) was developed that recognizes amino acids 25-30 of human and rat GLP-2-(1-33). UTTH-7 cross-reacts with N- and C-terminally modified forms of GLP-2, proglucagon, and the major proglucagon fragment. Analysis of rat ileal extracts demonstrated the presence of GLP-2-(1-33) as well as significant amounts of GLP-2-(3-33) (16 ± 7% of total GLP-2). The level of total immunoreactive GLP-2 in plasma from fasted rats was 700 ± 71 pg/ml, and this increased 3.6-fold (P <0.001) in 24-h fed rate. HPLC analysis demonstrated the presence of both GLP-2-(1-33) and GLP-2-(3-38) in plasma from fasted rats, with increments in both peptides in plasma from fed rats. Immunoreactive GLP-2 increased in plasma from human subjects 2 h after a meal, rising from 851 ± 230 to 1106 ± 211 pg/ml (P <0.05); 15 ± 4% of this immunoreactivity was accounted for by the presence of intact GLP-2. HPLC showed the presence of both GLP-2-(1-33) and GLP-2-(3-33) in plasma from fed humans. Incubation of human GLP-2-(1-33) with the enzyme dipeptidylpeptidase IV resulted in liberation of GLP-2-(3-33), whereas replacement of Ala 2 with Gly 2 prevented this cleavage. Thus, while GLP-2-(1-33) is a major circulating and tissue form of GLP-2. GLP-2-(3-33) is a significant component of immunoreactive GLP-2 in both intestine and plasma.

AB - Glucagon-like peptide-2 (GLP-2) has recently been identified as a stimulator of intestinal epithelial growth, prompting the development of RIA and HPLC methodologies to study this peptide in more detail. A GLP-2-specific antiserum (UTTH-7) was developed that recognizes amino acids 25-30 of human and rat GLP-2-(1-33). UTTH-7 cross-reacts with N- and C-terminally modified forms of GLP-2, proglucagon, and the major proglucagon fragment. Analysis of rat ileal extracts demonstrated the presence of GLP-2-(1-33) as well as significant amounts of GLP-2-(3-33) (16 ± 7% of total GLP-2). The level of total immunoreactive GLP-2 in plasma from fasted rats was 700 ± 71 pg/ml, and this increased 3.6-fold (P <0.001) in 24-h fed rate. HPLC analysis demonstrated the presence of both GLP-2-(1-33) and GLP-2-(3-38) in plasma from fasted rats, with increments in both peptides in plasma from fed rats. Immunoreactive GLP-2 increased in plasma from human subjects 2 h after a meal, rising from 851 ± 230 to 1106 ± 211 pg/ml (P <0.05); 15 ± 4% of this immunoreactivity was accounted for by the presence of intact GLP-2. HPLC showed the presence of both GLP-2-(1-33) and GLP-2-(3-33) in plasma from fed humans. Incubation of human GLP-2-(1-33) with the enzyme dipeptidylpeptidase IV resulted in liberation of GLP-2-(3-33), whereas replacement of Ala 2 with Gly 2 prevented this cleavage. Thus, while GLP-2-(1-33) is a major circulating and tissue form of GLP-2. GLP-2-(3-33) is a significant component of immunoreactive GLP-2 in both intestine and plasma.

UR - http://www.scopus.com/inward/record.url?scp=0030782159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030782159&partnerID=8YFLogxK

U2 - 10.1210/en.138.11.4837

DO - 10.1210/en.138.11.4837

M3 - Article

C2 - 9348213

AN - SCOPUS:0030782159

VL - 138

SP - 4837

EP - 4843

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 11

ER -